删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

厦门大学国家传染病诊断试剂与疫苗工程技术研究中心导师教师师资介绍简介-黄守杰

本站小编 Free考研考试/2021-05-09

一 基本情况

黄守杰(Shou-Jie Huang)教授级高级工程师
中华预防医学疫苗临床研究专业委员会会员


二 学习经历
2008年 获厦门大学生物化学与分子生物学硕士学位
1999年 获北京大学公共卫生学院医学学士学位
三 工作经历
2020年 厦门大学公共卫生学院 教授级高级工程师
2012年 厦门大学公共卫生学院 高级实验师
2011年 厦门大学公共卫生学院 实验师
2004年 厦门大学医学院 实验师
1999年 厦门大学医学院 助理实验师


四 主要研究方向
疫苗临床试验、传染病流行病学
五 科研
2006年至今从事疫苗临床试验和传染病流行病学研究,在疫苗临床试验领域具有丰富的经验。作为主要研究成员完善和构建疫苗临床试验质量保证体系。开展了戊肝疫苗、双价HPV、九价HPV、7D水痘、新冠等17项疫苗临床试验。其中戊肝疫苗于2012年全球首个成功上市,双价HPV疫苗于2019年国产首个成功上市。主持或参与国家自然科学基金、国家传染病重大科技专项等10多个项目。已在NEJM、Lancet、IJC、CMI等学术刊物发表论文60余篇。先后获得江苏省科学技术奖一等奖(2012年)、求是科技基金会杰出科技成就集体奖(2015年)等科研奖励。


代表性论文
1)Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans[J]. Nature communications, 2020, 11(1): 1-13.
2)Comparing Immunogenicity of the Escherichia coli-produced Bivalent Human Papillomavirus Vaccine in Females of Different Ages[J]. Vaccine, 2020, 38(39): 6096–6102.
3)Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals[J]. Human Vaccines & Immunotherapeutics, 2020, 16(7): 1630-1635.
4)Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China[J]. Annals of Oncology, 2019, 30(10): 1630-1637.
5)Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years[J]. Vaccine, 2019, 37(32): 4581-4586.
6)Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Science China-Life Sciences, 2020, 63(4):582-591.

7)Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial[J]. Journal of the National Cancer Institute, 2020, 112(2): 145-153.

8)Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study[J]. Clinical Infectious Diseases, 2020, 70(1): 82-89.

9)Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study[J]. International journal of cancer. 2019, 145(3): 807-816.

10)Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial[J]. Clinical Microbiology and Infection, 2019, 25(9): 1133-1139.

11)The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study[J]. International journal of cancer, 2018, 142(6): 1244-1251.

12)Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system[J]. Emerging Microbes & Infections, 2017, 6(1): 1-8.

13)Persistence of antibodies acquired by natural hepatitis E virus infection and the effects of vaccination [J]. Clinical Microbiology and Infection, 2017, 23 (5): 336.e1-336.e4.

14)Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study [J]. Emerging Microbes & Infections, 2016, 5(1): 1-8.

15)Immunogenicity and safety of an E. coli–produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial [J]. Vaccine, 2015, 33(32): 3940-3946.

16)Long-term efficacy of a hepatitis E vaccine [J]. New England Journal of Medicine, 2015, 372(10): 914-922.

17)Protective immunity against HEV [J]. Current opinion in virology, 2014, 5(1): 1-6.

18)Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial [J]. Human vaccines & immunotherapeutics, 2014, 10(2): 469-475.

19)Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity [J]. Clinical Microbiology and Infection, 2014, 20(6): O397-O405.

20)Profile of acute infectious markers in sporadic hepatitis E [J]. PloS one, 2010, 5(10): e13560.

21)Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial [J]. Lancet, 2010, 376(9744): 895-902.


相关话题/厦门大学 疫苗